CHICAGO — In renal cell carcinoma, adjuvant everolimus improved recurrence-free survival after nephrectomy but narrowly missed the benchmark for statistical significance, according to final results from the phase 3 EVEREST study.
“Up to one-third of patients who undergo curative-intent nephrectomy will end up developing metastatic recurrence, and for many years, surveillance alone remained standard management for these patients, with no benefit of adjuvant cytokine therapy being seen in early trials,” Christopher W. Ryan, MD, from the Oregon Health & Science University